SG11202103622SA - Combination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same - Google Patents
Combination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the sameInfo
- Publication number
- SG11202103622SA SG11202103622SA SG11202103622SA SG11202103622SA SG11202103622SA SG 11202103622S A SG11202103622S A SG 11202103622SA SG 11202103622S A SG11202103622S A SG 11202103622SA SG 11202103622S A SG11202103622S A SG 11202103622SA SG 11202103622S A SG11202103622S A SG 11202103622SA
- Authority
- SG
- Singapore
- Prior art keywords
- preparing
- same
- vaccine composition
- combination vaccine
- reduced dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201821038850 | 2018-10-12 | ||
| PCT/IN2019/050737 WO2020075184A1 (en) | 2018-10-12 | 2019-10-04 | Combination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202103622SA true SG11202103622SA (en) | 2021-05-28 |
Family
ID=68542707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202103622SA SG11202103622SA (en) | 2018-10-12 | 2019-10-04 | Combination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20210346483A1 (ar) |
| EP (1) | EP3863665A1 (ar) |
| JP (1) | JP7478144B2 (ar) |
| KR (1) | KR20210091158A (ar) |
| CN (1) | CN113164577A (ar) |
| AR (1) | AR116631A1 (ar) |
| AU (1) | AU2019359564A1 (ar) |
| BR (1) | BR112021006707A2 (ar) |
| CA (1) | CA3115803A1 (ar) |
| CO (1) | CO2021004556A2 (ar) |
| EA (1) | EA202190778A1 (ar) |
| JO (1) | JOP20190242A1 (ar) |
| MD (1) | MD4890B1 (ar) |
| MX (1) | MX2021004233A (ar) |
| PE (1) | PE20211648A1 (ar) |
| PH (1) | PH12021550812A1 (ar) |
| SG (1) | SG11202103622SA (ar) |
| TW (1) | TW202034948A (ar) |
| UY (1) | UY38412A (ar) |
| WO (1) | WO2020075184A1 (ar) |
| ZA (1) | ZA202103154B (ar) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200214A1 (ar) | 2019-09-03 | 2021-03-03 | Serum Institute Of India Pvt Ltd | تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها |
| CN112316126B (zh) * | 2020-10-29 | 2021-08-13 | 武汉生物制品研究所有限责任公司 | 一种氢氧化铝佐剂吸附百日咳菌毛(Fim)抗原制品的制备方法 |
| CN116355083B (zh) * | 2023-05-30 | 2023-09-08 | 国药中生生物技术研究院有限公司 | 特异性结合脊髓灰质炎病毒i型抗原的抗体 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE121629T1 (de) * | 1989-07-14 | 1995-05-15 | Praxis Biolog Inc | Stabile interleukine enthaltende impfstoffzusammensetzungen. |
| DK0835663T3 (da) | 1992-05-23 | 2010-02-01 | Glaxosmithkline Biolog Sa | Kombinerede vacciner omfattende Hepatitis B overfladeantigen og andre antigener |
| ES2325301T3 (es) | 1995-06-23 | 2009-09-01 | Glaxosmithkline Biologicals S.A. | Composicion de vacuna que comprende un antigeno polisacarido conjugado, adsorbido sobre fosfato de aluminio. |
| US6790445B1 (en) * | 1997-02-06 | 2004-09-14 | Merck & Co., Inc. | Preservatives for vaccines |
| ATE470434T1 (de) * | 1997-02-06 | 2010-06-15 | Merck Sharp & Dohme | Thimerosal-freie konservierungsmittel für impfstoffe |
| DK1028750T3 (da) | 1997-09-15 | 2006-05-22 | Sanofi Pasteur Msd | Fremgangsmåde til fremstilling af multivalente vacciner |
| GB9806456D0 (en) | 1998-03-25 | 1998-05-27 | Smithkline Beecham Biolog | Vaccine composition |
| EP1004314A1 (fr) | 1998-11-26 | 2000-05-31 | Pasteur Merieux MSD | Vaccin T.d. Polio rappel pour une population vaccinée ou sensibilisée |
| US20040258700A1 (en) * | 2003-06-23 | 2004-12-23 | Frimann Tine Holland | Vaccine formulation with a preservative |
| GB0405787D0 (en) | 2004-03-15 | 2004-04-21 | Chiron Srl | Low dose vaccines |
| GB0616226D0 (en) | 2006-08-15 | 2006-09-27 | Novartis Ag | Processes |
| ES2387582T3 (es) * | 2006-09-07 | 2012-09-26 | Glaxosmithkline Biologicals S.A. | Vacuna de combinación con cantidades reducidas del antígeno del virus de la polio |
| MY162658A (en) * | 2007-11-23 | 2017-06-30 | Shanghai Zerun Biotechnology Co Ltd | Genes encoding major capsid protein l1 of human papilloma virus and use of the same |
| PE20100365A1 (es) * | 2008-10-24 | 2010-05-21 | Panacea Biotec Ltd | Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion |
| CN103442730B (zh) * | 2011-01-05 | 2016-08-17 | 巴拉特生物技术国际有限公司 | 组合七价疫苗 |
| CN102133396B (zh) * | 2011-03-16 | 2013-10-16 | 中国人民解放军第三〇二医院 | 一种疫苗注射剂及其制备方法 |
| KR101864029B1 (ko) * | 2015-09-16 | 2018-06-01 | 주식회사 엘지화학 | 다회투여량 혼합 백신 조성물 |
| PE20200004A1 (es) * | 2016-08-26 | 2020-01-06 | Serum Institute Of India Pvt Ltd | Composicion de vacuna multivalente novedosa |
| GEP20227386B (en) * | 2017-07-18 | 2022-06-10 | Serum Institute Of India Pvt Ltd | Immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof |
-
2018
- 2018-10-12 JO JOP/2019/0242A patent/JOP20190242A1/ar unknown
-
2019
- 2019-10-04 CA CA3115803A patent/CA3115803A1/en active Pending
- 2019-10-04 JP JP2021520140A patent/JP7478144B2/ja active Active
- 2019-10-04 PE PE2021000499A patent/PE20211648A1/es unknown
- 2019-10-04 EP EP19802302.0A patent/EP3863665A1/en active Pending
- 2019-10-04 MX MX2021004233A patent/MX2021004233A/es unknown
- 2019-10-04 MD MDA20210028A patent/MD4890B1/ro unknown
- 2019-10-04 KR KR1020217014281A patent/KR20210091158A/ko active Search and Examination
- 2019-10-04 WO PCT/IN2019/050737 patent/WO2020075184A1/en unknown
- 2019-10-04 AU AU2019359564A patent/AU2019359564A1/en active Pending
- 2019-10-04 EA EA202190778A patent/EA202190778A1/ru unknown
- 2019-10-04 SG SG11202103622SA patent/SG11202103622SA/en unknown
- 2019-10-04 CN CN201980080962.3A patent/CN113164577A/zh active Pending
- 2019-10-04 US US17/284,529 patent/US20210346483A1/en active Pending
- 2019-10-04 BR BR112021006707-8A patent/BR112021006707A2/pt unknown
- 2019-10-10 UY UY0001038412A patent/UY38412A/es unknown
- 2019-10-10 AR ARP190102893A patent/AR116631A1/es unknown
- 2019-10-14 TW TW108136931A patent/TW202034948A/zh unknown
-
2021
- 2021-04-12 PH PH12021550812A patent/PH12021550812A1/en unknown
- 2021-04-12 CO CONC2021/0004556A patent/CO2021004556A2/es unknown
- 2021-05-10 ZA ZA2021/03154A patent/ZA202103154B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020075184A1 (en) | 2020-04-16 |
| CA3115803A1 (en) | 2020-04-16 |
| CO2021004556A2 (es) | 2021-04-30 |
| JP2022502469A (ja) | 2022-01-11 |
| BR112021006707A2 (pt) | 2021-07-27 |
| ZA202103154B (en) | 2022-03-30 |
| MD4890B1 (ro) | 2024-04-30 |
| CN113164577A (zh) | 2021-07-23 |
| PH12021550812A1 (en) | 2021-11-08 |
| TW202034948A (zh) | 2020-10-01 |
| EA202190778A1 (ru) | 2021-08-05 |
| JP7478144B2 (ja) | 2024-05-02 |
| JOP20190242A1 (ar) | 2020-04-12 |
| US20210346483A1 (en) | 2021-11-11 |
| KR20210091158A (ko) | 2021-07-21 |
| MD20210028A2 (ro) | 2021-11-30 |
| MX2021004233A (es) | 2021-08-16 |
| UY38412A (es) | 2020-04-30 |
| EP3863665A1 (en) | 2021-08-18 |
| AR116631A1 (es) | 2021-05-26 |
| PE20211648A1 (es) | 2021-08-24 |
| AU2019359564A1 (en) | 2021-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201814362D0 (en) | Composition and process for preparing vaccine | |
| ZA202103154B (en) | Combination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same | |
| SG11202003796XA (en) | Zika vaccines and immunogenic compositions, and methods of using the same | |
| IL290999A (en) | hbv vaccines and hbv treatment methods | |
| SG11202004863QA (en) | Zika vaccines and immunogenic compositions, and methods of using the same | |
| EP3983085A4 (en) | NEW ADJUVANT FOR ANIMAL AND HUMAN VACCINES | |
| GB201802339D0 (en) | Immunogenic composition | |
| IL291601A (en) | Neoglycoconjugates as vaccines and therapeutic tools | |
| IL275849B (en) | Influenza virus vaccines and their uses | |
| IL284233A (en) | Norovirus vaccine: formulations and methods | |
| EP3730620A4 (en) | CROSS-IMMUNIZATION ANTIGENIC VACCINE AND PROCESS FOR PREPARATION | |
| SG11201911930SA (en) | Methods and compositions for substance use disorder vaccine formulations and uses thereof | |
| EP3830109A4 (en) | METHODS AND COMPOSITIONS FOR ALPHAVIRUS VACCINATION | |
| GB201910794D0 (en) | Vaccine | |
| IL284249A (en) | A preparation that includes a vaccine additive | |
| IL282753A (en) | Immunogenic compounds | |
| IL258700A (en) | An excipient and a vaccine that includes it | |
| EP3615005A4 (en) | VACCINATION COMPOSITIONS AND METHODS | |
| IL282245A (en) | Methods and compositions of polypeptide-based vaccines | |
| ZA202105143B (en) | Pharmaceutical preparation for treating hepatitis b, preparation method therefor and use thereof | |
| IL285618A (en) | Adjuvants and vaccine formulations | |
| KR102130925B9 (ko) | 면역원성시스템 및 이를 포함한 동물 백신 | |
| IL273168A (en) | A compound for an epidural vaccine of hepatitis B and its production | |
| EP3897691A4 (en) | IL-10 VACCINES AND THEIR USES | |
| GB201811382D0 (en) | Vaccine |